Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics BusinessBusiness Wire • 10/31/22
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal CancerBusiness Wire • 10/04/22
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 08/30/22
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight DiagnosticsBusiness Wire • 08/17/22
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic CancersBusiness Wire • 08/15/22
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 ConferenceBusiness Wire • 08/04/22
Personalis, Inc. (PSNL) CEO John West on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual DiseaseBusiness Wire • 07/12/22
Personalis, Inc.'s (PSNL) CEO John West on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaBusiness Wire • 04/26/22
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic SalesBusiness Wire • 04/21/22
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA GeneBusiness Wire • 04/12/22
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ PlatformBusiness Wire • 04/12/22
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022Business Wire • 04/11/22